Completed PHASE2 INTERVENTIONAL 3-arm NCT01200485

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

A Randomized Phase 2 Study to Evaluate the Efficacy of Rasburicase in Patients at Risk for TLS During Two Cycles of Chemotherapy

Sponsor: M.D. Anderson Cancer Center

Conditions Leukemia Lymphoma

Interventions Allopurinol Rasburicase

Updated 7 times since 2017 Last updated: Jan 23, 2020 Started: Apr 30, 2011 Primary completion: Jul 31, 2016 Completion: Jul 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01200485, this PHASE2 trial focuses on Leukemia and Lymphoma and remains completed. Sponsored by M.D. Anderson Cancer Center, it has been updated 7 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Feb 2020 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Feb 2020 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center
Sanofi

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States